Propanc Health Group Corp (OTCMKTS:PPCH) a growing healthcare firm reported that it finalized a biomarker discovery deal with Adaptive Biotechnologies. Under the deal, Adaptive will use company’s patented immune profiling test, the immunoSEQ Assay, to allow an in-depth portrayal of the immune response to ailments being investigated in both the pre-clinical stage and in later clinical development measures focused on Propanc’s “PRP” therapeutic.

The study of immune responses in outside the cell tumor microenvironment, where Propanc’s drug is thought to have a key role, may identify patient enrolments more likely to respond to treatment depending on their immune status.

The significance

The CEO James Nathanielsz said that Propanc management is delighted to finalize the research deal with Adaptive Biotechnologies. The company is right at the forefront in the immuno-oncology industry. Propanc’s team look forward to know more about PRP, its mechanisms, its impact on the region around the cancer cell and more importantly subjects’ response to treatment. All these factors will boost the development initiatives of PRP and the ongoing research discovery plans.

Chad Robins, the President, Co-Founder and CEO of Adaptive, said that as a leader firm in immuno sequencing, they are set to work closely with firms like Propanc to support discovery and innovations in cancer therapeutics. The technology continues to shows the significance of revealing the adaptive immune system and its role in understanding a patient’s immune response to new treatments.

The momentum

Last month has been a strong month for Propanc Health Group Corp (OTCMKTS:PPCH). The stock price traded close to $0.06 in the first week of last month and from there on climbed up to record a high over $0.125. In last trading session, the stock price of Propanc declined over 2% to close the trading session at $0.0870. The decline came at a share volume of 3.04 million compared to average share volume of 14.22 million.

Next articleWhat Is The Buzz Surrounding Green Endeavors Inc (OTCMKTS:GRNE)?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.